|
|
|
|
LEADER |
02043nam a2200361 u 4500 |
001 |
EB002001078 |
003 |
EBX01000000000000001163979 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
210907 r ||| eng |
245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Levodopa/carbidopa intestinal gel (Duodopa -- Abbvie Corporation)
|h Elektronische Ressource
|b indication : Parkinson's disease
|
246 |
3 |
1 |
|a Drug reimbursement recommendation Levodopa/carbidopa intestinal gel (Duodopa)
|
246 |
3 |
1 |
|a Levodopa/carbidopa intestinal gel (Duodopa -- Abbvie Corporation)
|
250 |
|
|
|a Version 1.0
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, 2018 Aug
|
300 |
|
|
|a 1 PDF file (9 pages)
|
653 |
|
|
|a Insurance, Health, Reimbursement
|
653 |
|
|
|a Parkinson Disease / drug therapy
|
653 |
|
|
|a Canada
|
653 |
|
|
|a Carbidopa / therapeutic use
|
653 |
|
|
|a Cost-Benefit Analysis
|
653 |
|
|
|a Antiparkinson Agents / economics
|
653 |
|
|
|a Levodopa / therapeutic use
|
710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH common drug review
|
500 |
|
|
|a "Final"
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK539327
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 330
|
520 |
|
|
|a The CADTH Canadian Drug Expert Committee recommends that levodopa/carbidopa intestinal gel (LCIG) be reimbursed for the treatment of patients with advanced levodopa-responsive Parkinson disease (PD) who do not have satisfactory control of motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of PD medicinal products, and for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomyjejunostomy tube required for administration
|